Free Trial
→ This little-known fund tracks gold and pays out weekly (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ablynx NV stock logo
ABLYF
Ablynx
$50.63
$50.63
$12.50
▼
$55.04
$3.81B1.995,063 shsN/A
Repligen Corporation stock logo
RGEN
Repligen
$176.94
-6.2%		$178.05
$100.99
▼
$198.87
$9.99B1.081.31 million shs4.47 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ablynx NV stock logo
ABLYF
Ablynx
0.00%0.00%0.00%0.00%0.00%
Repligen Corporation stock logo
RGEN
Repligen
0.00%+0.01%-0.16%+25.48%+19.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ablynx NV stock logo
ABLYF
Ablynx
$50.63
$50.63
$12.50
▼
$55.04
$3.81B1.995,063 shsN/A
Repligen Corporation stock logo
RGEN
Repligen
$176.94
-6.2%		$178.05
$100.99
▼
$198.87
$9.99B1.081.31 million shs4.47 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ablynx NV stock logo
ABLYF
Ablynx
0.00%0.00%0.00%0.00%0.00%
Repligen Corporation stock logo
RGEN
Repligen
0.00%+0.01%-0.16%+25.48%+19.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ablynx NV stock logo
ABLYF
Ablynx
0.00
N/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
2.89
Moderate Buy$178.570.92% Upside

Current Analyst Ratings Breakdown

Latest RGEN and ABLYF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/28/2026
Repligen Corporation stock logo
RGEN
Repligen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$185.00 ➝ $200.00
10/19/2026
Repligen Corporation stock logo
RGEN
Repligen
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetHold$145.00 ➝ $180.00
10/8/2026
Repligen Corporation stock logo
RGEN
Repligen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C-) ➝ Hold (C)
10/7/2026
Repligen Corporation stock logo
RGEN
Repligen
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$175.00 ➝ $225.00
9/29/2026
Repligen Corporation stock logo
RGEN
Repligen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/28/2026
Repligen Corporation stock logo
RGEN
Repligen
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
9/9/2026
Repligen Corporation stock logo
RGEN
Repligen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$195.00 ➝ $225.00
8/13/2026
Repligen Corporation stock logo
RGEN
Repligen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D+) ➝ Hold (C-)
(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ablynx NV stock logo
ABLYF
Ablynx
$62.73M60.74N/AN/A$2.71 per share18.68
Repligen Corporation stock logo
RGEN
Repligen
$738.26M13.53$3.42 per share51.79$37.06 per share4.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ablynx NV stock logo
ABLYF
Ablynx
-$122.67MN/AN/AN/AN/AN/AN/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
$48.89M-$0.21N/A66.773.21-1.47%5.49%3.93%N/A

Latest RGEN and ABLYF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/27/2026Q3 2026
Repligen Corporation stock logo
RGEN
Repligen
$0.4628$0.53+$0.0672-$0.68$206.70 million$209.31 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
0.27
9.88
7.64

Institutional Ownership

CompanyInstitutional Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
Repligen Corporation stock logo
RGEN
Repligen
97.64%

Insider Ownership

CompanyInsider Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
Repligen Corporation stock logo
RGEN
Repligen
0.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ablynx NV stock logo
ABLYF
Ablynx
N/A75.25 millionN/ANot Optionable
Repligen Corporation stock logo
RGEN
Repligen
2,00056.44 million56.10 millionOptionable

Recent News About These Companies

10,547 Repligen Corporation $RGEN Shares Sold by Sterling Capital Management LLC
October 31 at 4:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-10547-repligen-corporation-rgen-shares-sold-by-sterling-capital-management-llc-2026-10-31/
Barclays Remains a Buy on Repligen (RGEN)
October 30 at 10:32 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RGEN/pressreleases/8526657/barclays-remains-a-buy-on-repligen-rgen/
RGEN Q3 deep dive: Margin headwinds and BioLife integration shape improved full-year outlook
October 30 at 5:29 PM  |  msn.comhttps://www.msn.com/en-us/news/other/rgen-q3-deep-dive-margin-headwinds-and-biolife-integration-shape-improved-full-year-outlook/ar-AA2grFbv
Repligen (NASDAQ:RGEN) Sees Large Volume Increase - Should You Buy?
October 30 at 1:00 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-repligen-nasdaq-rgen-sees-large-volume-increase-should-you-buy-2026-10-30/
Repligen Corporation announced that it expects to receive $458.6 million in funding
October 30 at 12:27 PM  |  marketscreener.comM
Repligen prices $1B convertible notes due 2031 to refinance 2028 debt
October 30 at 12:27 PM  |  streetinsider.comhttps://www.streetinsider.com/Equity+Offerings/Repligen+prices+%241B+convertible+notes+due+2031+to+refinance+2028+debt/27260365.html
Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity
October 30 at 7:26 AM  |  rttnews.comhttps://www.rttnews.com/3706410/repligen-announces-1-bln-convertible-notes-offering-to-extend-debt-maturity.aspx
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
October 30 at 6:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/30/3392091/24603/en/repligen-announces-1-billion-private-convertible-senior-notes-transaction.html
Repligen (NASDAQ:RGEN) Shares Climb 4.5% After Strong Earnings
October 30 at 1:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31166669
Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations
October 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/repligen-nasdaq-rgen-exceeds-q3-2026-expectations-full-year-outlook-slightly-exceeds-expectations/ar-AA2gaIfB
Repligen (NASDAQ:RGEN) Shares Up 4.5% Following Better-Than-Expected Earnings
October 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-repligen-nasdaq-rgen-shares-up-45-following-better-than-expected-earnings-2026-10-28/
Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
October 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4958009-repligen-corporation-rgen-q3-2026-earnings-call-transcript
Repligen (RGEN) Takes $41.2 Million Impairment Charge As Quarterly Profit Turns To Loss
October 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/repligen-rgen-takes-41-2-201406897.html
Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance
October 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/repligen-rgen-could-12-undervalued-011039090.html
Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN)
October 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/record-revenue-outlook-could-game-210656172.html
Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Is Priced In
October 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/repligen-rgen-stock-looks-fairly-180724578.html
Repligen slips as investors weigh filtration weakness against strong Q3 results
October 27, 2026  |  quiverquant.comQ
Repligen Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
October 27, 2026  |  marketscreener.comM
Repligen (RGEN) Q3 2026 Earnings Call Transcript
October 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/repligen-rgen-q3-2026-earnings-155921919.html
Repligen (NASDAQ:RGEN) Shares Gap Down - Here's What Happened
October 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-repligen-nasdaq-rgen-shares-gap-down-heres-what-happened-2026-10-27/
What Repligen (RGEN) Said on Its Q3 Earnings Call
October 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/transcript-what-repligen-rgen-said-on-its-q3-earnings-call-2026-10-27/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ablynx stock logo

Ablynx OTCMKTS:ABLYF

$50.63 0.00 (0.00%)
As of 04/30/2019

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Repligen stock logo

Repligen NASDAQ:RGEN

$176.94 -11.70 (-6.20%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$176.94 0.00 (0.00%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas